Certara Inc
CERT
查看详细走势图
7.230USD
-0.150-2.03%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.15B总市值
106.51市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.03%
5天
-17.75%
1月
-23.81%
6月
-35.79%
今年开始到现在
-17.93%
1年
-46.88%
查看详细走势图
TradingKey Certara Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Certara Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在软件与IT服务行业排名82/482位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.38。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Certara Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Certara Inc亮点
亮点风险
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
估值合理
公司最新PE估值106.51，处于3年历史合理位
机构加仓
最新机构持股185.12M股，环比增加0.54%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值26.58K
活跃度降低
近期活跃度降低，过去20天平均换手率0.19
分析师目标
根据
14
位分析师
买入
评级
12.375
目标均价
+62.61%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Certara Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Certara Inc简介
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.
公司代码CERT
公司Certara Inc
CEOFeehery (William F)
网址https://www.certara.com/
相关品种
